Rhythm Pharmaceuticals RYTM
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Rhythm Pharmaceuticals (RYTM) Core Market Data and Business Metrics
Latest Closing Price
$51.96Price-Earnings Ratio
-11.97Total Outstanding Shares
63.22 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
222 Berkeley Street, Boston, MA, 02116
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 561,590 Shares | 8.39 | 3/14/2025 | 4,710,022 Shares |
| 568,315 Shares | 9.05 | 2/28/2025 | 5,145,240 Shares |
| 399,279 Shares | 13.55 | 2/14/2025 | 5,410,357 Shares |
| 471,586 Shares | 10.87 | 1/31/2025 | 5,127,767 Shares |
| 550,151 Shares | 9.91 | 1/15/2025 | 5,453,889 Shares |
| 583,471 Shares | 9.02 | 12/31/2024 | 5,265,779 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-48.17 Million |
| Net Cash Flow From Operating Activities | $-113.88 Million |
| Net Cash Flow From Financing Activities | $191.24 Million |
| Net Cash Flow From Operating Activities, Continuing | $-113.88 Million |
| Net Cash Flow From Financing Activities, Continuing | $191.24 Million |
| Net Cash Flow | $29.19 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Revenues | $130.13 Million |
| Basic Earnings Per Share | $-4.34 |
| Net Income/Loss | $-260.60 Million |
| Nonoperating Income/Loss | $5.25 Million |
| Operating Income/Loss | $-265.50 Million |
| Income/Loss From Continuing Operations After Tax | $-260.60 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-264.75 Million |
| Comprehensive Income/Loss Attributable To Parent | $-264.75 Million |
| Other Comprehensive Income/Loss | $-4.14 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Assets | $374.20 Million |
| Liabilities And Equity | $392.27 Million |
| Inventory | $18.74 Million |
| Current Liabilities | $115.52 Million |
| Assets | $392.27 Million |
| Other Non-current Assets | $17.44 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||